Jose-Marie El-Amm, MD
Nephrology · Oklahoma City, OKNPI 1619914611
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,167 of the $2,428 with a category attached, or 89.3%. 18 manufacturers reported payments, led by Veloxis Pharmaceuticals, Inc. at 30.0% of the total. Reporting peaked in 2019 at $799 and has fallen 68.5% since, to $252 in 2025. That places this record below the midpoint for nephrology clinicians in OK, where the typical reported total is $2,111.
Across 61 payments — averaging $39.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Veloxis Pharmaceuticals, Inc.$729
- AstraZeneca$576
- Eurofins Viracor, LLC$162
- Merck$146
- Amgen$125
- Vifor Pharma, Inc.$125
- plus $565 from 12 others
Across 87 payments — averaging $486.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$38K
- Shire North American Group Inc$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- E.r. Squibb & Sons, L.L.C.$1K
What the payments were for
- Food & beverage$2,16789%
- Education$1526%
- Entertainment$1094%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Veloxis Pharmaceuticals, Inc. | 17 | $729 |
| AstraZeneca(2 entities) | 14 | $576 |
| Eurofins Viracor, LLC | 3 | $162 |
| Merck | 3 | $146 |
| Amgen | 1 | $125 |
| Vifor Pharma, Inc. | 1 | $125 |
| Sanofi | 1 | $92 |
| Bayer | 4 | $81 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $80 |
| Novartis | 3 | $74 |
| Vertex | 1 | $73 |
| Travere Therapeutics, Inc. | 4 | $59 |
| Dexcom, Inc. | 1 | $21 |
| La Jolla Pharmaceutical Company | 1 | $20 |
| Mallinckrodt Enterprises LLC | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Calliditas Therapeutics US Inc. | 1 | $15 |
| Abbott | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,428 in reported general payments places this provider in the 50th percentile of 106 nephrology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 27 | $17,928 |
| Valganciclovir Hcl | 80 | $17,727 |
| LokelmaSodium Zirconium Cyclosilicate | 16 | $10,248 |
| FarxigaDapagliflozin Propanediol | 12 | $7,636 |
| Cinacalcet Hcl | 19 | $3,058 |
| Potassium Chloride | 61 | $1,795 |
| Novolog FlexpenInsulin Aspart | 13 | $1,750 |
| Mycophenolate Mofetil | 15 | $1,745 |
| Carvedilol | 142 | $1,628 |
| Famotidine | 87 | $1,457 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 199 | $1,366 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $1,297 |
| Prednisone | 155 | $1,203 |
| Amlodipine Besylate | 159 | $1,120 |
| Atorvastatin Calcium | 86 | $856 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaLokelma, Farxiga | $576 | $17,88428 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 106 nephrology providers in Oklahoma.
Other nephrology in Oklahoma City
- Celeste BoeckmanOklahoma City$90K
- Joseph GhataOklahoma City$45K
- Benjamin CowleyOklahoma City$36K
- Brad CarterOklahoma City$13K
- Laura RankinOklahoma City$11K
- Gary BondOklahoma City$9K
- Sudhir KhannaOklahoma City$7K
- Jawaid JamalOklahoma City$7K
- Patrick ReevesOklahoma City$6K
- Bradley LongOklahoma City$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.